Proviron and Tamoxifen Interaction: Avoid | Peptide Database

The classic PCT SERM. Tamoxifen blocks estrogen negative feedback at the hypothalamus and pituitary, driving LH and FSH elevation to restart endogenous testosterone production after suppression from anabolic steroids or exogenous testosterone. Accelerates the return of serum testosterone to baseline levels following cycle cessation, reducing the duration of the hypogonadal window and associated symptoms such as fatigue, low libido, and muscle loss. Blocks estrogen receptor activation in breast tissue during aromatizable steroid cycles, preventing the development of gynecomastia without reducing systemic estrogen levels. Can reduce early-stage gynecomastia symptoms (tenderness, lump formation) by competitively blocking estrogen at the breast tissue receptor level. Less effective once fibrotic tissue has formed. FDA-approved for adjuvant treatment of estrogen receptor-positive breast cancer in both pre- and postmenopausal women. Reduces recurrence rates and mortality when used for 5-10 years following primary treatment. FDA-approved for chemoprevention in women at high risk of developing breast cancer. The NSABP P-1 trial demonstrated a 49% reduction in invasive breast cancer incidence.

The most common nootropic use case for 9-Me-BC is the restoration of dopaminergic function following periods of stimulant use (amphetamines, methylphenidate, high-dose caffeine) that may have downregulated dopamine receptors or depleted dopaminergic tone. By upregulating TH and promoting dopaminergic neuron health, 9-Me-BC theoretically supports the recovery of normal motivational drive and reward sensitivity. Evidence is limited to animal models and user reports. Used in the bodybuilding and performance-enhancement community during PCT (post-cycle therapy) phases following SARM or prohormone cycles, where hormonal suppression can reduce dopaminergic tone. The rationale is to support neurological recovery alongside endocrine recovery. 9-Me-BC has been studied in animal models of Parkinson's disease, where it demonstrated the ability to restore dopaminergic neuron function and promote neurite regrowth in lesioned dopaminergic pathways. These findings are promising but remain preclinical, with no human trials conducted. The combination of TH upregulation, neurotrophic activity, and anti-neuroinflammatory effects positions 9-Me-BC as a potentially broad neuroprotective agent for the dopaminergic system. However, the phototoxicity risk and lack of human data significantly complicate any long-term neuroprotective application. Through enhanced dopamine synthesis capacity, users report improvements in baseline motivation, initiative, and the ability to engage in cognitively demanding tasks. Effects are described as subtle and cumulative rather than acutely stimulating.